The School for Mental Health and Neuroscience (MHeNs) strives to advance our understanding of brain-behaviour relationships by using an approach integrating various disciplines in neuro- and behavioural science, medicine, and the life sciences. MHeNs performs high-impact neuroscience research and educates master’s students and PhD researchers. MHeNs performs translational research, meaning practical collaboration between researchers in the lab and in the hospital and in close collaboration with the Faculty for Psychology and Neuroscience and School of Business and Economics (Centre for Integrative Neuroscience).
With the knowledge acquired today, we move forward working towards a better future for the patients of today and tomorrow. That is why we collaborate in crossroads.
Coming together at crucial intersections is where MHeNs researchers (from the five MHeNs research themes) and clinicians from the clinical pillars from MUMC+ Brain and Nerve Centre (BNC) and Centre for Ophthalmology meet and work together, opening the door to new discoveries. Discoveries for current patients and those of the future.
MHeNs and BNC collaborate in 11 specialisms, aimed at patients with complex disorders of the brain and nervous system. The research collaborations occur in the so-called clinical pillars. The outcomes of this team research performances will lead to advanced evidence-based insights, innovative decision-making, better directions, highly developed innovations, technologies and treatments that can have considerable societal impact. Explore our crossroads in the following 5 research themes below.
Cognition and Dementia
Hearing and Balance
Vision and Ophthalmology
Mood, Anxiety and Trauma
Psychosis and Neurodevelopment
MHeNs’ PhD programme promotes a high level of competence in a specific research field, but also in more generic, transferrable skills that are important for professional careers in research, education, or clinical practice.
Oxytocin may be able to support memory in people with Alzheimer’s disease. This is the conclusion of a study led by Maastricht University in which oxytocin was administered to mice with Alzheimer’s-related problems. The research is based on epigenetics, the external effects that turn parts of our DNA on or off during our lifetime.
The European Commission has awarded €23 million to set up a new platform for drug repurposing: the use of existing drugs in diseases other than those for which they were originally developed. In the next seven years UM will develop the platform REPO4EU (precision drug REPurpOsing for Europe) together with various international partners. A congress in Maastricht held on 2-3 September kicked off the project.
Prof. Frans Verhey appointed Officer in the Order of Oranje-Nassau